Expert consensus on treatment for stage III non‐small cell lung cancer

Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation with a multiple disciplinary team, which allows the developm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medicine advances (Online) 2023-03, Vol.1 (1), p.3-13
Hauptverfasser:	Wu, Yi‐Long, Lu, Shun, Zhou, Qinghua, Zhang, Li, Cheng, Ying, Wang, Jie, Wang, Buhai, Hu, Chengping, Lin, Lizhu, Zhong, Wenzhao, Song, Yong, Yang, Nong, Dong, Xiaorong, Zhao, Jian, Yang, Haihong, Guo, Hui, Yan, Xiaolong, Liu, Hongxu, Ma, Rui, Lin, Jie, Liu, Siyang, Chen, Chun, Wang, Lifeng, Zhou, Chengzhi, Zhou, Ming, Wu, Fang, Yang, Xue‐Ning, Du, Yingying, Yao, Yu, Shao, Yang, Hong, Shaodong, Cui, Jiuwei, Quan, Xueping, Chen, Rongrong, Wu, Jiayan, Zhang, Jiatao, Zhou, Jianya, Wang, Binchao, Cheng, Chao, Wang, Huijuan, Liu, Jingjing, Wu, Lin, Huang, Yan, Kuang, Yukun, Zhang, Yongchang, Hu, Jia, Yang, Jinji, Feng, Weineng, Su, Wenmei, Fan, Yun, Yang, Fan, Chen, Ming, Tang, Kejing, Pan, Yi, Shen, Peng, Liu, Anwen, Zhang, Haibo, Liang, Wenhua, Zhou, Qing, Ma, Zhiyong, Cai, Xiuyu, Liu, Hui, Chen, Longfei, Chuai, Shaokun, Shan, Jianzhen, Zheng, Yanfang, You, Changxuan, Zhu, Xiaoxia, Li, Li, Zhang, Tongmei, Tu, Haiyan, Lin, Wurong, Zhang, Xuchao, Zhou, Penghui, Ke, Zunfu, Liang, Huiying
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Cancer therapies Chemotherapy Clinical trials consensus Disease Epidermal growth factor FDA approval Immunotherapy Kinases Ligands Lung cancer Lymphatic system Medical diagnosis Metastasis multiple disciplinary comprehensive treatment Mutation Radiation therapy Remission (Medicine) Retinoblastoma stage III non‐small cell lung cancer Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation with a multiple disciplinary team, which allows the development of a proposal for clinical diagnosis and treatment. In this consensus, stage III NSCLC is divided into two types (operable and inoperable) according to different clinical conditions. Resectable NSCLC is further subdivided into two conditions (with or without driver genes). For each clinical scenario, this consensus emphasizes that the foundation of any medical decisions regarding the optimal diagnostic or therapy procedure is scientific evidence from clinical research. Finally, based on the level of evidence and strength of recommendations, this consensus provides recommendations for the management of stage III NSCLC from six perspectives. The objective of this consensus is to help clinicians choose the best treatment and promote the standardization of stage III NSCLC diagnosis and treatment in China.
ISSN:	2834-4405 2834-4391 2834-4405
DOI:	10.1002/med4.7